Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
US Army
McKesson
Covington
Express Scripts
Fish and Richardson
Chubb
AstraZeneca
QuintilesIMS

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,074,256

« Back to Dashboard

Which drugs does patent 9,074,256 protect, and when does it expire?

Patent 9,074,256 protects FANAPT and is included in one NDA.

This patent has five patent family members in four countries.
Summary for Patent: 9,074,256
Title:Method of predicting a predisposition to QT prolongation
Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Inventor(s): Lavedan; Christian (Potomac, MD), Volpi; Simona (Derwood, MD), Licamele; Louis (Potomac, MD)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:13/263,076
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,074,256

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-001 May 6, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Try a Free Trial
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-002 May 6, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Try a Free Trial
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-003 May 6, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Try a Free Trial
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-004 May 6, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,074,256

PCT Information
PCT FiledApril 05, 2010PCT Application Number:PCT/US2010/029943
PCT Publication Date:October 14, 2010PCT Publication Number: WO2010/117941

International Patents Family Members for US Patent 9,074,256

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2757723 ➤ Try a Free Trial
European Patent Office 2416778 ➤ Try a Free Trial
Japan 2012522534 ➤ Try a Free Trial
Japan 5881598 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cipla
Argus Health
McKesson
Cerilliant
Fish and Richardson
UBS
AstraZeneca
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.